214 related articles for article (PubMed ID: 19940966)
1. Environmental risk assessment for medicinal products containing genetically modified organisms.
Anliker B; Longhurst S; Buchholz CJ
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):52-7. PubMed ID: 19940966
[TBL] [Abstract][Full Text] [Related]
2. Regulatory requirements for clinical trial and marketing authorisation application for cell-based medicinal products.
Salmikangas P; Flory E; Reinhardt J; Hinz T; Maciulaitis R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):24-9. PubMed ID: 19940964
[TBL] [Abstract][Full Text] [Related]
3. Regulatory requirements for clinical trial and marketing authorisation application for gene therapy medicinal products.
Schüle S; Renner M; Longhurst S; Narayanan G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):30-7. PubMed ID: 20012927
[TBL] [Abstract][Full Text] [Related]
4. [Clinical trials with advanced therapy medicinal products].
Schüssler-Lenz M; Schneider CK
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):68-74. PubMed ID: 20011994
[TBL] [Abstract][Full Text] [Related]
5. [Requirements for long-term follow-up on efficacy and safety of advanced therapy medicinal products. Risk management and traceability].
Klug B; Reinhardt J; Schröder C
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):58-62. PubMed ID: 19949763
[TBL] [Abstract][Full Text] [Related]
6. Legal basis of the Advanced Therapies Regulation.
Jekerle V; Schröder C; Pedone E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):4-8. PubMed ID: 19940965
[TBL] [Abstract][Full Text] [Related]
7. CAT--the new committee for advanced therapies at the European Medicines Agency.
Celis P
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):9-13. PubMed ID: 20084354
[TBL] [Abstract][Full Text] [Related]
8. The Genetically Modified Organism Medicinal Framework in Europe, United States, and Japan: Underlying Scientific Principles and Considerations Toward the Development of Gene Therapy and Genetically Modified Cell-Based Products.
Bachtarzi H; Farries T
Hum Gene Ther Clin Dev; 2019 Sep; 30(3):114-128. PubMed ID: 31111736
[No Abstract] [Full Text] [Related]
9. Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union.
Beattie S;
Hum Gene Ther; 2021 Oct; 32(19-20):997-1003. PubMed ID: 33843251
[TBL] [Abstract][Full Text] [Related]
10. Regulations governing veterinary medicinal products containing genetically modified organisms in the European community.
Moulin G
Rev Sci Tech; 2005 Apr; 24(1):101-7. PubMed ID: 16110880
[TBL] [Abstract][Full Text] [Related]
11. Environmental risk assessment of advanced therapies containing genetically modified organisms in the EU.
Whomsley R; Palmi Reig V; Hidalgo-Simon A
Br J Clin Pharmacol; 2021 Jun; 87(6):2450-2458. PubMed ID: 33600022
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of GMO regulatory requirements for AAV vectors in the EU and Japan focusing on the shedding data and containment measures.
Mizoguchi H; Fleischmann T; Komuro M; Hirai T; Ikeda A; Saito K; Watahiki T; Tajima G
Expert Opin Biol Ther; 2024 Jun; 24(6):529-542. PubMed ID: 38919146
[TBL] [Abstract][Full Text] [Related]
13. The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
Carr M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):20-3. PubMed ID: 20101799
[TBL] [Abstract][Full Text] [Related]
14. Regulation of genetically modified organisms (GMOs) in the European Union: principles of risk assessment.
Anadón A; Roda L; Martínez-Larrañaga MR
Vet Hum Toxicol; 2004 Dec; 46(6):340-1. PubMed ID: 15587259
[TBL] [Abstract][Full Text] [Related]
15. GM Risk Assessment.
Sparrow PA
Methods Mol Biol; 2009; 478():315-30. PubMed ID: 19009454
[TBL] [Abstract][Full Text] [Related]
16. Temporary derogation from European environmental legislation for clinical trials of genetically modified organisms for coronavirus disease 2019.
Iglesias-Lopez C
Cytotherapy; 2021 Jan; 23(1):10-11. PubMed ID: 33082093
[TBL] [Abstract][Full Text] [Related]
17. [Regulation (EC) No. 1394/2007 on advanced therapy medicinal products : Incorporation into national law].
Dwenger A; Strassburger J; Schwerdtfeger W
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):14-9. PubMed ID: 20033662
[TBL] [Abstract][Full Text] [Related]
18. [The EU law on genetically modified organisms: the European Commission changes the strategy in order to allow, restrict, or prohibit its culture].
González Vaqué L
Rev Derecho Genoma Hum; 2010; (33):217-40. PubMed ID: 21510337
[TBL] [Abstract][Full Text] [Related]
19. Hurdles of environmental risk assessment procedures for advanced therapy medicinal products: comparison between the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A; Montané J
Crit Rev Toxicol; 2019 Aug; 49(7):580-596. PubMed ID: 31846383
[TBL] [Abstract][Full Text] [Related]
20. Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany.
Renner M; Anliker B; Sanzenbacher R; Schuele S
Adv Exp Med Biol; 2015; 871():87-101. PubMed ID: 26374214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
